Phosphoinositide 3-kinase (PI3K) mediates insulin actions by relaying signals from insulin receptors (IRs) to downstream targets. The p110a catalytic subunit of class IA PI3K is the primary insulin-responsive PI3K implicated in insulin signaling. We demonstrate here a new mode of spatial regulation for the p110a subunit of PI3K by PAQR3 that is exclusively localized in the Golgi apparatus. PAQR3 interacts with p110a, and the intracellular targeting of p110a to the Golgi apparatus is reduced by PAQR3 downregulation and increased by PAQR3 overexpression. Insulin-stimulated PI3K activity and phosphoinositide (3,4,5)-triphosphate production are enhanced by Paqr3 deletion and reduced by PAQR3 overexpression in hepatocytes. Deletion of Paqr3 enhances insulin-stimulated phosphorylation of AKT and glycogen synthase kinase 3b, but not phosphorylation of IR and IR substrate-1 (IRS-1), in hepatocytes, mouse liver, and skeletal muscle. Insulin-stimulated GLUT4 translocation to the plasma membrane and glucose uptake are enhanced by Paqr3 ablation. Furthermore, PAQR3 interacts with the domain of p110a involved in its binding with p85, the regulatory subunit of PI3K. Overexpression of PAQR3 dose-dependently reduces the interaction of p85a with p110a. Thus, PAQR3 negatively regulates insulin signaling by shunting cytosolic p110a to the Golgi apparatus while competing with p85 subunit in forming a PI3K complex with p110a. Diabetes 62: [444][445][446][447][448][449][450][451][452][453][454][455][456] 2013 
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Phosphoinositide 3-kinase (PI3K) mediates insulin actions by relaying signals from insulin receptors (IRs) to downstream targets. The p110a catalytic subunit of class IA PI3K is the primary insulin-responsive PI3K implicated in insulin signaling. We demonstrate here a new mode of spatial regulation for the p110a subunit of PI3K by PAQR3 that is exclusively localized in the Golgi apparatus. PAQR3 interacts with p110a, and the intracellular targeting of p110a to the Golgi apparatus is reduced by PAQR3 downregulation and increased by PAQR3 overexpression. Insulin-stimulated PI3K activity and phosphoinositide (3, 4, 5) triphosphate production are enhanced by Paqr3 deletion and reduced by PAQR3 overexpression in hepatocytes. Deletion of Paqr3 enhances insulin-stimulated phosphorylation of AKT and glycogen synthase kinase 3b, but not phosphorylation of IR and IR substrate-1 (IRS-1), in hepatocytes, mouse liver, and skeletal muscle. Insulin-stimulated GLUT4 translocation to the plasma membrane and glucose uptake are enhanced by Paqr3 ablation. Furthermore, PAQR3 interacts with the domain of p110a involved in its binding with p85, the regulatory subunit of PI3K. Overexpression of PAQR3 dose-dependently reduces the interaction of p85a with p110a. Thus, PAQR3 negatively regulates insulin signaling by shunting cytosolic p110a to the Golgi apparatus while competing with p85 subunit in forming a PI3K complex with p110a. Diabetes 62: [444] [445] [446] [447] [448] [449] [450] [451] [452] [453] [454] [455] [456] 2013 I nsulin resistance is closely associated with the pathogenesis of metabolic diseases, especially type 2 diabetes (1). The phosphoinositide 3-kinase (PI3K)/ AKT pathway is central to the metabolic actions of insulin (2, 3) , and the PI3K family is grouped into three classes (I-III) according to substrate preference and sequence homology. Class IA PI3K comprises heterodimers of a p85 regulatory subunit (p85a, p85b, and p55g) and a p110 catalytic subunit (p110a, p110b, and p110d). In response to stimulation by growth factors such as insulin, the p110 subunits catalyze the production of a lipid second messenger phosphatidylinositol-3,4,5-trisphosphate at the plasma membrane (PM). This second messenger, in turn, activates the serine/threonine kinase AKT and other downstream effectors (4, 5) . The catalytic subunits p110a and p110b are expressed ubiquitously, whereas p110d is mainly localized in hematopoietic cells (2, 3) and likely has actions related to immune cell development and activation (6, 7) . Mice deficient in either p110a or p110b display embryonic lethality (8, 9) , and p110a is considered the primary determinant of insulin signaling and insulin sensitivity in vivo. Mice heterozygous for a kinase-dead mutation in p110a have hyperinsulinemia, glucose intolerance, and increased obesity (10) , whereas p110b does not contribute to insulin receptor substrate (IRS)-associated PI3K activity (10) . Moreover, conditional deletion of p110a in the liver reduces insulin sensitivity and impairs glucose tolerance in the mouse (11) , which is not rescued by overexpression of p110b. Finally, a pharmacological approach using a panel of inhibitors specific for different catalytic subunits of PI3K has indicated that p110a is the primary insulin-responsive PI3K required for insulin signaling (12) . Interestingly, a role for p110b on insulin action and metabolic control remains unresolved, although it may act to aid in setting a phenotypic threshold for p110a activity (12) . Selective deletion of p110b in the mouse liver leads to a certain degree of insulin resistance without affecting AKT phosphorylation, suggesting a kinaseindependent mechanism of metabolic regulatory control (13) .
PAQR3 belongs to the progesterone and AdipoQ receptor (PAQR) family in which AdipoR1 and AdipoR2 (i.e., PAQR1 and PAQR2) function as cell surface receptors for adiponectin, an adipocyte-secreted cytokine that regulates glucose and lipid metabolism (14, 15) . Although PAQR3 shares high sequence homology with AdipoR1/PAQR1 and AdipoR2/PAQR2 (16), it is not localized on the PM (17, 18) . Instead, PAQR3 is exclusively localized in the Golgi apparatus and was renamed RKTG (Raf kinase trapping to Golgi) due to its spatial regulation of Raf kinase (17) . Subsequent characterization of PAQR3 indicates that it may function as a tumor suppressor by negatively regulating the Ras to ERK signaling cascade (19) (20) (21) . Given that PAQR3 regulates Ras/ERK and G protein-coupled receptor signaling pathways by sequestering Raf kinase or Gb subunit to the Golgi apparatus (17, 22) , we hypothesized that PAQR3 might also regulate insulin signaling in a spatial manner. As p110a is the primary molecule within the PI3K family that mediates insulin signaling and insulin sensitivity (10-12), we focused on the potential regulation of p110a by PAQR3. In this study, we provide in vitro and in vivo evidence for a unique role of PAQR3 in the spatial regulation of insulin signaling via a capacity to sequester the p110a subunit of PI3K to the Golgi apparatus, thereby limiting its activity.
RESEARCH DESIGN AND METHODS
Animal studies. All animals were maintained and used in accordance with the guidelines of the Institutional Animal Care and Use Committee of the Institute for Nutritional Sciences. All of the experimental procedures were carried out in accordance with the Chinese Academy of Sciences ethics commission with an approval number 2010-AN-8. Paqr3-null mice were generated as previously described, with deletion of the exon 2 whole (17, 19) . The Paqr3 2/2 mice were crossed with C57BL/6J for at least five generations. For studies of in vivo insulin signaling, male mice fed with normal chow at 8-10 weeks of age were fasted overnight, followed by intraperitoneal injection of insulin (5 units/kg body weight). The mice were killed after 5 min, and the liver and gastrocnemius muscle were excised and snap frozen for analyses. Confocal microscopy and quantification of fluorescence signals. The confocal analyses with overexpression experiments were performed as previously reported (17, 22) . The Golgi localization was determined by immunostaining with antibodies against either Golgin-97 or GM130, two well-characterized Golgi markers. For the study of localization of endogenous p110a in HEK293T cells, the plasmid for PAQR3 short hairpin RNA (shRNA) or its control were transfected into cells, and the cells were fixed and stained with anti-human p110a and Golgin-97 antibodies. The fluorescence signals of endogenous p110a were mainly localized in three areas: the cytosol, Golgi apparatus, and nucleus ( Fig. 2A) . Assuming that nucleus-localized p110a is not able to participate in p110a-mediated signaling on the PM, we calculated the percentage of Golgi-localized p110a signal and cytosol-localized p110a signal, and the signals from both compartments add to 100%. The Golgi-localized p110a signal was obtained by direct measurement of the fluorescence signals delimited by Golgi marker Golgin-97 (and delimited by PAQR3 staining in the case of PAQR3 overexpression, as another Golgi marker could not be used due to limitation of secondary antibodies; in addition, PAQR3 itself is exclusively localized in the Golgi apparatus). The cytosol-localized p110a signals were obtained by subtracting the total fluorescence signals of a cell from the signals in the Golgi apparatus and the nucleus (delimited by Hoechst 33342 staining). The images presented in the figures were captured using standardized setting and exposure times. More than 100 cells were observed in three independent experiments, and at least 20 cells were randomly chosen and measured in each experiment group. For the assay using green fluorescent protein linked to the pleckstrin homology domain (GFP-PH) to analyze in vivo activation of PI3K, HepG2 cells were transfected with GFP-AKT2-PH together with a Myc-tagged PAQR3 or the pCS2+MT vector as control, followed by culture for 18 h and then stimulation with 100 nmol/L insulin for various times. The fluorescence intensity and the subcellular distribution of GFP-PH were quantified using LSM by Zeiss Confocal Microscopy Software. The integrated density of pixels was calculated for the whole cell and for the subregion of the PM compartment. The fluorescence signal in the PM compartment was calculated by subtracting the integrated density value of the subregion of PM from the value of the whole cell. The percentage of GFP-PH signal in PM was then divided by the integrated density value of the whole cell. Twenty cells were measured in each experimental group. Fractionation of Golgi membranes from mouse liver. Golgi membranes were purified as described previously (23, 24) . In brief, mouse livers were homogenized in 0.5 mol/L sucrose in PM buffer (potassium phosphate, with pH at 6.7, and 5 mmol/L MgCl 2 ) with protease inhibitor cocktail (Thermo, Rockford, IL). The homogenate was layered on top of 0.86 mol/L sucrose, overlaid with 0.25 mol/L sucrose, and centrifuged for 60 min at 29,000 rpm in a rotor (SW-41; Beckman Coulter, Brea, CA). The 0.5 mol/L sucrose layer was collected (cytosol fraction). The interface between the 0.5 and 0.86 mol/L sucrose (intermediate fraction) was diluted to 0.25 mol/L sucrose and layered on top of 1.3 and 0.5 mol/L sucrose. After centrifugation for 30 min at 8,000 rpm in a rotor (SW-41), the enriched Golgi membranes were collected at the 0.5/1.3 mol/L sucrose interface. Equal amounts of protein of liver homogenate, cytosol, intermediate fraction, and Golgi membranes were used for immunoblotting. Preparation of the cytosolic and membranous fractions. The cytosolic and membranous fractions were separated by using a Cell Fraction Kit (Biovision, Milpitas, CA). In brief, HEK293T cells were homogenized on ice, the homogenate was centrifuged for 10 min at 700g at 4°C, and the supernatant was a cytosol-containing fraction. The pellet was resuspended in Membrane Extraction Buffer Mix (Biovision), followed by centrifuging for 5 min at 1,000g at 4°C, and the membrane protein was collected in the supernatant. Equal amounts of cytosol or membrane protein were used for immunoblotting in the PAQR3 overexpression experiment, and 1.5-fold more membrane proteins than the cytosolic proteins were used in the PAQR3 knockdown experiment. . The whole-cell lysate was incubated with antibodies against IRS-1 or phosphotyrosine overnight, followed by incubation with protein A/G-Sepharose for 2 h at 4°C, and washed with TNE buffer (10 mmol/L Tris-HCl at pH 7.4, 150 mmol/L NaCl, 5 mmol/L EDTA, and 0.1 mmol/L sodium orthovanadate). The PI3K activity was measured in immunoprecipitates with a PI3K ELISA kit (Echelon Biosciences, Salt Lake City, UT). Phosphoinositide (3,4,5)-triphosphate (PIP3) content in the cells was measured with a PIP3 ELISA kit, according to a protocol that was previously reported (25) . Immunohistochemistry for GLUT4. Skeletal muscle was fixed in 4% paraformaldehyde/PBS, frozen in OCT (Optimal Cutting Temperature; SAKURA, Torrance, CA), sectioned, and immunostained. Samples were permeabilized and blocked with 1% BSA, 3% normal goat serum, and 0.1% Triton X-100 in PBS, followed by antibody incubation and mounting. For quantitation of cell surface localization of GLUT4, Zeiss Confocal Microscopy Software was used to quantify total fluorescent values of GLUT4 and the signals localized at the cell surface. The percentage of GLUT4 signal at cell surfaces was divided by the total GLUT4 signal. Sections from three individual mice were quantified for each sample. Glucose uptake. Mice were anesthetized after 6 h of fasting. Skeletal muscle was dissected and rinsed in Krebs-Henseleit bicarbonate (KHB) buffer supplemented with 0.1% BSA and followed by incubation in PBS or 100 nmol/L insulin for 15 min at 30°C. The tissues were then treated with 1 mmol/L 2-deoxyglucose (2DG) for 20 min. All KHB buffers were pregassed with 95% O 2 -5% CO 2 . Glucose uptake was stopped by washing the tissues in ice-cold PBS. Subsequent to assays, muscle strips were solubilized in 10 mM Tris-HCl, pH 8.0, followed by detection of the amount of 2DG using a 2DG Uptake Measurement Kit (Cosmo, Tokyo, Japan). Statistical analysis. Student t test was used for most of the statistical analysis. Mann-Whitney U test was used for the Western blot data in which n = 3. A two-sided test was performed with all the analyses.
RESULTS
PAQR3 tethers PI3K p110a subunit to the Golgi apparatus. We first analyzed whether PAQR3 was able to tether the PI3K subunit to the Golgi apparatus. When p110a was overexpressed in HeLa cells, it was diffusely distributed in the cytosol (Fig. 1A) . Intriguingly, when coexpressed with PAQR3, p110a was almost completely mobilized to the Golgi apparatus (Fig. 1A) . On the other hand, overexpression of PAQR3 did not promote the Golgi localization of overexpressed p85a (Fig. 1A) . In addition, overexpression of PAQR3 had no effect on the subcellular distribution of AKT and glycogen synthase kinase 3b (GSK3b) (Supplementary Fig. 1 ), two other major players involved in insulin signaling. Next, we used coimmunoprecipitation assays to determine whether PAQR3 can form a complex with p110a. When both PAQR3 and p110a were overexpressed, immunoprecipitation of p110a could pull down PAQR3 (Fig. 1B) . Conversely, immunoprecipitation of PAQR3 could also pull down p110a (Fig. 1C) . Furthermore, immunoprecipitation of endogenous PAQR3 with an anti-PAQR3 antibody could copurify endogenous p110a (Fig. 1D) , further confirming an interaction between PAQR3 and p110a.
We next investigated the intracellular localization of endogenous p110a under the condition of PAQR3 knockdown ( Fig. 2A) . Previously, we identified a PAQR3 shRNA (no. 3-121) that has a high efficiency for knockdown of endogenous PAQR3 ( Supplementary Fig. 2 ) (21). We found that knockdown by a specific PAQR3 shRNA could markedly reduce Golgi localization of endogenous p110a in comparison with a control shRNA (FG-12) (Fig. 2A) . In FG-12-expressing cells, 27% of endogenous p110a was localized in the Golgi apparatus and 73% in the cytosol (Fig. 2B) . However, the percentage Golgi localization of p110a was reduced to ;12% by PAQR3 knockdown (Fig.  2B) . Concomitantly, endogenous p110a in the cytosol compartment was elevated to 88% from 73% by PAQR3 knockdown (Fig. 2B ). These data, therefore, further corroborate the functional role of PAQR3 in altering the subcellular distribution of p110a.
FIG. 1. PAQR3 tethers the p110a subunit to the Golgi apparatus and interacts with p110a. A: PAQR3 tethers overexpressed p110a, but not p85a, to the Golgi apparatus. HeLa cells were transiently transfected with the plasmids as indicated, followed by immunofluorescence staining and confocal
We also used a biochemical approach to purify Golgi complexes from mouse liver to assess the localization of endogenous p110a. In isolated liver from wild-type mice, p110a could be clearly detected in the Golgi fraction that coexisted with Golgi markers GM130 and Golgin-97 (Fig.  2C) . However, ablation of PAQR3 led to marked reduction of Golgi compartmentalization of p110a in the liver (Fig.  2C) , thus providing strong evidence that PAQR3 is implicated in Golgi localization of endogenous p110a protein.
Furthermore, we investigated the relative distribution of p110a in the cytosolic and membranous fractions. Silencing of PAQR3 expression caused a redistribution of p110a from the membranous fraction to the cytosol (Fig. 2D) . Conversely, overexpression of PAQR3 reduced cytosolic distribution of p110a and increased membranous distribution of p110a (Fig. 2E) . These data thus provide further evidence that PAQR3 can alter the subcellular compartmentalization of p110a. PAQR3 is able to regulate PI3K activity. On the basis of our observations, we propose a model to illustrate the spatial regulation of PI3K by PAQR3 (Fig. 3A) . We predict that PAQR3 negates insulin signaling by sequestering intracellular PI3K to the Golgi apparatus via the interaction with the p110a subunit. We next tested this model by directly analyzing the effect of PAQR3 on PI3K activity using two strategies. First, we measured the amount of PIP3, a direct product of PI3K. In primary mouse hepatocytes, as expected, insulin increased the level of PIP3 (Fig. 3B) , which was further enhanced by ablation of Paqr3 (Fig. 3B) . Second, we analyzed PI3K activity using primary mouse hepatocytes. Insulin administration could rapidly stimulate PI3K activity, as assayed by immunoprecipitation of PI3K by antibodies against either IRS-1 or phosphorylated tyrosine (Fig. 3C and D) . Deletion of Paqr3 not only increased the basal PI3K activity but also enhanced insulin-stimulated PI3K activity ( Fig. 3C and D) . Conversely, overexpression of PAQR3 in HepG2 cells could significantly inhibit insulin-stimulated PIP3 production (Fig. 3E ) and PI3K activity (Fig. 3F) , corroborating the observations in Paqr3-deleted hepatocytes.
We also used an in vivo marker to directly analyze PI3K activation within the cell. A GFP fusion protein linked to the PH domain of AKT2 can be recruited to the PM upon insulin stimulation (26, 27) . Similar to the previous report (26) , insulin treatment was able to rapidly elevate translocation of GFP-PH protein to the PM in HepG2 hepatocytes (Fig. 4) . Interestingly, overexpression of PAQR3 markedly abrogated insulin-induced translocation of GFP-PH protein to the PM (Fig. 4) . These data indicate that PAQR3 is directly involved in the functional regulation of PI3K, thus providing further evidence to corroborate the proposed model in which PI3K is modulated by PAQR3 in a spatial manner (Fig. 3A) . PAQR3 modulates insulin signaling in vitro and in vivo. We next analyzed the effect of PAQR3 on insulin signaling in hepatocytes. Insulin signaling is propagated by a series of protein phosphorylation events (28) , initiated by insulin binding, activation, and phosphorylation of the insulin receptor (IR), and the subsequent phosphorylation of IRS, which functions as an adaptor for the p85/p110 PI3K complex. Activated PI3K generates PIP3, which recruits proteins, such as AKT, that contain specific lipidbinding domains (i.e., the PH domain). Activated AKT then phosphorylates a large array of proteins; one of the best characterized is GSK3. We analyzed the effect of PAQR3 on insulin-induced phosphorylation of four key proteins: IRb (at Tyr1150/1151), IRS-1 (at Tyr608), AKT (at Ser473), and GSK3b (at Ser9). Insulin treatment induced rapid phosphorylation of IRb, IRS-1, AKT, and GSK3b in hepatocytes ( Fig. 5A and Supplementary Fig. 3) , and the phosphorylation of AKT and GSK3b, but not IRb and IRS-1, was markedly enhanced by Paqr3 deletion (Fig. 5A and Supplementary Fig. 3 ). In contrast, overexpression of PAQR3 in HepG2 cells inhibited insulin-induced phosphorylation of AKT and GSK3b, but not IRb and IRS-1, in HepG2 hepatocytes (Fig. 5B and Supplementary Fig. 4) .
To investigate the in vivo role of PAQR3 on insulin signaling, we analyzed insulin signaling in the liver and skeletal muscle, two major insulin-responsive tissues. We administered insulin to wild-type and Paqr3-deleted (Paqr3 2/2 ) mice fed with normal chow. Paqr3 2/2 mice did not have any noticeable phenotype under normal resting conditions (17) . As expected, insulin administration initiated rapid phosphorylation of IRb, IRS-1, AKT, and GSK3b in mouse liver and skeletal muscle ( Fig. 6A and B) . Deletion of Paqr3 had no effect on insulin-induced phosphorylation of IRb and IRS-1, whereas insulin-stimulated phosphorylation of AKT and GSK3b was apparently enhanced by Paqr3 ablation (Fig. 6A and B) . The basal level of GSK3b phosphorylation was also elevated in the skeletal muscle of Paqr3 2/2 mice (Fig. 6B) . Collectively, these data indicate that PAQR3 is able to modulate insulin signaling in vitro and in vivo. Furthermore, these findings demonstrate that PAQR3 exerts its effects on insulin signaling downstream of IRS but upstream of AKT, the place at which PI3K acts, consistent with our proposed model (Fig. 3A) . PAQR3 regulates insulin-induced glucose uptake in skeletal muscles. To further investigate the potential function of PAQR3 on insulin action, we analyzed whether PAQR3 could alter glucose uptake in skeletal muscles, one of the major physiological functions of insulin. We analyzed the translocation of GLUT4 of skeletal muscles upon insulin stimulation. As expected, insulin treatment could induce translocation of a portion of endogenous GLUT4 to the cell surface (Fig. 7A) . Intriguingly, the insulin-induced translocation of GLUT4 to the PM was profoundly elevated by Paqr3 2/2 ablation ( Fig. 7A and B) . In addition, insulinstimulated glucose uptake to the skeletal muscle was also enhanced by Paqr3 2/2 deletion (Fig. 7C) . Collectively, these data reveal that PAQR3 not only alters insulin signaling but also affects the physiological actions of insulin. PAQR3 prevents p85 subunit from forming a complex with p110a. We next analyzed the functional domains of PAQR3 and p110a that are involved in their interaction. Using a coimmunoprecipitation assay and various truncated versions of PAQR3 that we previously analyzed (17,18), we observed that the NH 2 -terminal 71 amino acid residues of PAQR3 (PAQR3-N71) were sufficient to mediate the interaction with p110a (Fig. 8A) . Further deletion of the NH 2 terminus of PAQR3 abrogated its interaction with p110a (Fig. 8A) . In addition, PAQR3-N71 was able to inhibit insulin-stimulated AKT phosphorylation, similar to the effect of full-length PAQR3 ( Supplementary Fig. 5 ), indicating that the NH 2 terminus of PAQR3 is sufficient to mediate the inhibitory effect of PAQR3 on insulin signaling.
FIG. 3. PAQR3 is directly involved in the regulation of PI3K activity. A:
A model of PAQR3 regulation on insulin signaling through shunting p110a to the Golgi apparatus. B-D: Insulin-stimulated PIP3 production and PI3K activity are increased by Paqr3 ablation in mouse hepatocytes. Primary hepatocytes isolated from Paqr3-ablated mice and their littermate controls were treated with insulin for the times indicated, followed by measurement of the PIP3 level (B) and PI3K enzyme activity (C and D). Data are shown as mean 6 SD (n = 3 for each group). **P < 0.01 between wildtype and Paqr3 2/2 cells at each time point.^P < 0.05 and^^P < 0.01 between insulin-treated and insulin-untreated cells with the same genotype. E and F: Insulin-stimulated PIP3 production and PI3K activity are inhibited by PAQR3 overexpression. HepG2 cells, transfected with PAQR3-expressing plasmid or the vector control, were treated with insulin for the length of time as indicated, followed by measurement of the PIP3 level (E) and PI3K enzyme activity (F). The data are shown as mean 6 SD. *P < 0.05 and **P < 0.01 between control and PAQR3-overexpressing cells at each time point.^P < 0. Overexpression of PAQR3 reduces insulin signaling. HepG2 cells were transiently transfected with a Myc-tagged PAQR3 plasmid as indicated, treated with insulin (100 nmol/L) for 15 min, and followed by immunoblotting. The expression of transfected PAQR3 was detected by an anti-Myc antibody. For both A and B, five independent experiments were performed and gave rise to similar results. The relative ratios of phosphorylated IRb vs. total IRb, phosphorylated IRS-1 vs. b-actin, phosphorylated AKT vs. total AKT, and phosphorylated GSK3b vs. total GSK3b were obtained by densitometric analysis, with the data shown under the immunoblots (mean 6 SD). *P < 0.05 and **P < 0.01 between wild type (wt) and Paqr3 2/2 or between vector and PAQR3-overexpression groups with the same treatment.^P < 0.05 and^^P < 0.01 between saline-and insulinstimulated cells.
We next used PAQR3-N71 to map the domain of p110a implicated in its interaction with PAQR3. Intriguingly, the p85 binding domain of p110a was sufficient to mediate the interaction with PAQR3 (Fig. 8B) . On the basis of this finding, we hypothesized that PAQR3 might negate PI3K activity by reducing complex formation between the p85 subunit and p110a. To test this hypothesis, we analyzed the effect of PAQR3 on the p110a-p85a interaction. When PAQR3 was overexpressed, it could dose-dependently reduce the interaction of p110a with p85a (Fig. 8C) . These data, therefore, indicate that PAQR3 negatively modulates PI3K activity by preventing the p85 subunit from binding to p110a while sequestering p110a to the Golgi apparatus.
PAQR3 expression is altered in insulin-resistant conditions, and Paqr3 ablation increases insulin sensitivity. We next investigated the expression level of PAQR3 in obese and insulin-resistant mice either induced by high-fat diet (HFD) or caused by genetic deletion of leptin (ob/ob mice). The mRNA level of PAQR3 was elevated in the livers of both HFD and ob/ob mice ( Fig. 9A and  B) . In addition, the mRNA level of PAQR3 was increased in glucosamine-induced insulin-resistant hepatocytes (Fig.  9C ). These data, therefore, indicate that the expression level of PAQR3 is associated with the development of insulin resistance.
We also analyzed whether PAQR3 is implicated in the modulation of insulin sensitivity in vivo. The body weight FIG. 6 . Insulin signaling is enhanced by Paqr3 deletion in mouse tissues. Insulin-stimulated phosphorylation of AKT and GSK3b, but not of IRb and IRS-1, is enhanced by Paqr3 deletion in the liver (A) and skeletal muscle (B). Paqr3-deficient mice and the littermate controls (at 8-10 weeks of age) fed with normal chow were fasted for 12 h, followed by intraperitoneal injection of saline or insulin. The animals were killed at 5 min after injection, and the livers and skeletal muscle were used in immunoblotting with the antibodies as indicated. The experiments were repeated at least three times for each tissue with similar results. The relative ratios of phosphorylated IRb vs. total IRb, phosphorylated IRS-1 vs. actin, phosphorylated AKT vs. total AKT, and phosphorylated GSK3b vs. total GSK3b were obtained by density analysis with the data shown in the right panels (means 6 SEM). *P = 0.10 between wild-type (wt) and Paqr3 2/2 groups with the same treatment.^P = 0.10 between saline-and insulininjected mice with the same genotype. Two-sided Mann-Whitney U test was used in the statistical analysis. 2/2 mice that had been injected with either PBS or insulin was sectioned and stained with antibody for GLUT4. The sections were counterstained with Hoechest 33342. Original magnification 340. The arrow indicates apparent translocation of GLUT4 to the cell surface. The percentage of GLUT4 in the cell surface is shown in B. C: Glucose uptake is regulated by PAQR3. Strips of skeletal muscle isolated from wt or Paqr3 2/2 mice were incubated in the absence (before treatment) or presence of 100 nM insulin prior to incubation in the presence of 1 mmol/L 2DG, followed by measurement of 2DG uptake. Six mice per group were used for the assay. For both B and C, the data are presented as mean 6 SEM. *P < 0.05 between wt and Paqr3 2/2 groups with the same treatment.^P < 0.05 and^P < 0.01 between PBS-and insulin-treated mice with the same genotype. (A high-quality digital representation of this figure is available in the online issue.) and glucose tolerance test of the mice (at 12 weeks of age) were not significantly altered by Paqr3 deletion (Fig. 9D and  E) . However, the insulin sensitivity, as determined by insulin tolerance test, was apparently elevated by Paqr3 deletion (Fig. 9F) , thus providing additional in vivo evidence that PAQR3 is implicated in the modulation of insulin signaling.
DISCUSSION
Subcellular compartmentalization is now recognized as a means to fine-tune intracellular signal transduction. For example, Ras proteins are spatially and temporally trafficked within cells, depending on the extracellular stimuli and cellular context (29) . Compartmentalized signaling controls the intensity of signaling output and modulates cell function by altering the distribution and/or sequestration of signaling molecules. Specifically, distinct subcellular partitioning of endogenous subunits of PI3K has been reported. The p110b subunit localizes to the nucleus, and such localization is required for p110b to implement its effect on cell survival (30); similarly, Golgi-localized p110d is crucial for its regulation of tumor necrosis factor trafficking and secretion (31) . In contrast, the subcellular compartmentalization of the p110a subunit has proved elusive despite its principal role within the PI3K family in mediating insulin signaling (10) (11) (12) .
In this study, we report a previously unrecognized mode of spatial regulation of p110a by PAQR3, a transmembrane protein specifically localized in the Golgi apparatus (17) . Through its interaction with p110a, PAQR3 sequesters p110a to the Golgi apparatus, thereby reducing insulininduced, p110a-mediated signaling. Based on immunostaining, under basal conditions, endogenous p110a was mainly localized in three areas: the cytosol, Golgi apparatus, and nucleus ( Fig. 2A) . It is reasonable to assume that only the cytosol-localized p110a is available to participate in IRmediated PI3K signaling on the PM. Hence, we evaluated the relative partitioning of p110a between the Golgi and cytosol as an indication of the potential contribution of PAQR3-mediated Golgi compartmentalization of p110a to p110a-mediated signaling. We found that the presence or absence of PAQR3 can clearly change the balance between FIG. 8. PAQR3 reduces p85a binding with p110a. HEK293T cells were transiently transfected with the plasmids as indicated. The cell lysate was used in immunoblotting (IB) and immunoprecipitation (IP) using the antibodies as indicated. A: Interaction of the NH 2 -terminal end of PAQR3 with p110a. Two PAQR3 mutants were used in the assay: PAQR3-N71 contained the NH 2 -terminal 71 amino acid residues fused to GFP, and PAQR3-N41-60 contained 20 amino acid residues fused to GFP. B: Interaction of PAQR3-N71 with different functional domains of p110a. The functional domains of p110a are shown in B (top) as darkened boxes with the number of amino acid residues marked in the bottom. C: PAQR3 overexpression dose-dependently reduces the interaction between p110a and p85a, as measured by competition for coimmunoprecipitation.
cytosolic and Golgi-localized p110a. Knockdown of PAQR3 in HEK293T cells increased cytosolic p110a (Fig.  2A) . Concomitantly, the Golgi-localized p110a was reduced by PAQR3 knockdown (Fig. 2A) . Using the data in HEK293T cells as a calculation reference, complete deletion of Paqr3 would deplete all Golgi-localized p110a and result in a change of cytosolic p110a from 73 to 100%, leading to a 37% net increase in cytosolic p110a available for its signaling. Consistently, ablation of Paqr3 leads to an ;20-50% increase in PIP3 production and PI3K activity (Fig. 3B-D) , ;30-50% increase in insulin signaling, as judged by insulin-stimulated phosphorylation of AKT and GSK3b (Figs. 5 and 6), and ;30-40% elevation in insulinstimulated GLUT4 translocation to the cell surface and glucose uptake (Fig. 7) . Based on these data, we propose that PAQR3-mediated alteration in p110a compartmentalization may contribute to an ;30-50% change in insulinstimulated PI3K activity in the liver and skeletal muscle.
In highlighting the important contribution of PAQR3 to p110a-mediated signaling, this immunolocalization was complemented by our biochemical analysis using purified, isolated Golgi fractions, where Golgi localization of endogenous p110a was abrogated by Paqr3 ablation (Fig.  2C) . Consistently, the relative distribution of p110a in the cytosolic and membranous fractions is altered by the expression level of PAQR3 ( Fig. 2D and E) . Most importantly, deletion of Paqr3 leads to an increase in insulin-stimulated PI3K activity and PIP3 production in hepatocytes (Fig. 3B-D) . On the other hand, overexpression of PAQR3 reduces insulin-stimulated PI3K activity and PIP3 production ( Fig. 3E  and F) . Collectively, these data provide compelling evidence that PAQR3 is able to regulate the compartmentalization and activity of p110a.
Experiments aimed at mapping the domains involved in the interaction between PAQR3 and p110a reveal that the p85 binding domain of p110a mediates the interaction of p110a with PAQR3 (Fig. 8B) . Furthermore, overexpression of PAQR3 could dose-dependently reduce the interaction of p110a with p85 (Fig. 8C ). These data, therefore, indicate that PAQR3 negatively modulates PI3K activity by preventing p85 from forming a complex with p110a while sequestering p110a to the Golgi apparatus. Based on these data, we propose that p110a-mediated insulin signaling is modulated by the intracellular availability of PAQR3. Cells with a high expression level of PAQR3 would sequester a greater proportion of p110a in the Golgi apparatus, thereby decreasing the cytosolic portion of p110a available to relay the signaling from the IR to downstream effectors, and leading to a reduction in insulin action. In agreement with this idea, our data indicate that the expression level of PAQR3 is correlated with the development of insulin resistance. The mRNA level of Paqr3 was elevated in the livers of both HFD and ob/ob mice as well as in glucosamine-induced insulin-resistant hepatocytes (Fig. 9A-C) . Consistently, deletion of Paqr3 could increase insulin sensitivity in vivo (Fig. 9F) . These findings, therefore, indicate that changes of PAQR3 expression may represent a new mechanism underlying the compromised PI3K activity under pathophysiological conditions. It has previously been demonstrated that IRS-associated PI3K activity is decreased significantly in ob/ob mouse liver (32) and that AKT activity is reduced in the liver and skeletal muscle in diabetic rats (33) . It will be intriguing to determine in the future whether the comprised PI3K activity observed in these studies as well as in human diabetic patients is caused by alterations of PAQR3 expression.
FIG. 9.
PAQR3 expression is altered in insulin-resistant conditions, and Paqr3 deletion increases insulin sensitivity. A-C: The mRNA level of PAQR3 was analyzed in the liver of mice fed with normal chow (NC) or HFD for 16 weeks (n = 7 for NC and n = 8 for HFD) (A), in the liver of wildtype and ob/ob mice (n = 6 for each group) (B), and in glucosamine-treated primary mouse hepatocytes (C). All data are shown as means 6 SEM. *P < 0.05 and **P < 0.01 between the two groups. D-F: The effect of Paqr3 deletion on body weight (D), glucose tolerance test (E), and insulin tolerance test (F). The mice were ;12 weeks of age at the time of the experiment (n = 8 for each group). All the data are shown as means 6 SEM, and the P value from two-sided Student t test is indicated.
Considering the importance of PAQR3 in modulating PI3K activity, it will be crucial to identify the factors or conditions involved in regulating PAQR3 transcription and/or availability. Finally, modulating the expression of PAQR3 or its interaction with p110a may comprise a new strategy to control PI3K activity to combat insulin resistance.
